RxDoctor Payments Data

Brian Seeck, MD

Cardiovascular Disease · Washington, MONPI 1689714289

Payments from drug & device makers

$10,443in general payments, 2019–2025

Across 475 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boehringer Ingelheim$879
  • Novartis$763
  • Johnson & Johnson$620
  • Novo Nordisk$573
  • Boston Scientific$459
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$1,03010%
  • Food & beverage$9,34689%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,443 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$264,659
Medicare patients
1,250
Services billed
4,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,013$926,128
XareltoRivaroxaban283$241,937
OzempicSemaglutide173$222,697
Repatha SureclickEvolocumab183$153,537
JardianceEmpagliflozin67$74,059
EntrestoSacubitril/Valsartan63$59,497
MounjaroTirzepatide32$51,376
TrulicityDulaglutide38$37,778
Praluent PenAlirocumab29$23,372
BrilintaTicagrelor37$20,512
Bumetanide258$9,259
Flecainide Acetate254$8,161
Atorvastatin Calcium803$7,864
Diltiazem 24hr Er (Cd)Diltiazem Hcl262$6,998
Metoprolol Succinate653$5,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$415$926,1281,013 claims
Johnson & JohnsonXarelto$620$241,937283 claims
Novo NordiskOzempic$573$222,697173 claims
Lilly USA, LLCMounjaro, Trulicity$155$89,15470 claims
Boehringer IngelheimJardiance$879$74,05967 claims
NovartisEntresto$763$59,49763 claims
AstraZenecaBrilinta$136$20,51237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →